{"id":"https://openalex.org/W2624253981","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps1126","title":"A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.","display_name":"A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2624253981","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps1126","mag":"2624253981"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.tps1126","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps1126","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps1126","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057580348","display_name":"Steven Jay Isakoff","orcid":"https://orcid.org/0000-0002-6677-1014","observed_orcids":["https://orcid.org/0000-0002-6677-1014"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J. Isakoff","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069056507","display_name":"Sara M. Tolaney","orcid":"https://orcid.org/0000-0002-5940-8671","observed_orcids":["https://orcid.org/0000-0002-5940-8671"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara M. Tolaney","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051532432","display_name":"Nadine Tung","orcid":"https://orcid.org/0000-0003-1422-3734","observed_orcids":["https://orcid.org/0000-0003-1422-3734"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nadine M. Tung","raw_affiliation_strings":["Beth Israel Deaconess Medical Center and Dana-Farber Harvard Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center and Dana-Farber Harvard Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035762260","display_name":"Sylvia Adams","orcid":"https://orcid.org/0000-0003-4737-1952","observed_orcids":["https://orcid.org/0000-0003-4737-1952"]},"institutions":[{"id":"https://openalex.org/I4390039310","display_name":"NYU Langone\u2019s Laura and Isaac Perlmutter Cancer Center","ror":"https://ror.org/00sa8g751","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933","https://openalex.org/I4390039310"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sylvia Adams","raw_affiliation_strings":["Perlmutter Cancer Center, New York University School of Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Perlmutter Cancer Center, New York University School of Medicine, New York, NY","institution_ids":["https://openalex.org/I4390039310","https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090789911","display_name":"Hatem Hussein Soliman","orcid":"https://orcid.org/0000-0001-6644-2264","observed_orcids":["https://orcid.org/0000-0001-6644-2264"]},"institutions":[{"id":"https://openalex.org/I2613432","display_name":"University of South Florida","ror":"https://ror.org/032db5x82","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]},{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hatem Hussein Soliman","raw_affiliation_strings":["H. Lee Moffitt Cancer Center and University of South Florida, Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center and University of South Florida, Tampa, FL;","institution_ids":["https://openalex.org/I2613432","https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063493321","display_name":"Elena F. Brachtel","orcid":"https://orcid.org/0000-0002-6109-2848","observed_orcids":["https://orcid.org/0000-0002-6109-2848"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elena F Brachtel","raw_affiliation_strings":["Department of Pathology, Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034418316","display_name":"Karleen R. Habin","orcid":"https://orcid.org/0000-0001-8296-4134","observed_orcids":["https://orcid.org/0000-0001-8296-4134"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karleen R. Habin","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011405509","display_name":"Louisa J Bauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Louisa J Bauer","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052735318","display_name":"Leif William Ellisen","orcid":"https://orcid.org/0000-0003-0444-7910","observed_orcids":["https://orcid.org/0000-0003-0444-7910"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leif W. Ellisen","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061431553","display_name":"Mariano Severgnini","orcid":"https://orcid.org/0000-0001-6783-8500","observed_orcids":["https://orcid.org/0000-0001-6783-8500"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mariano Severgnini","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112035683","display_name":"William Thomas Barry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Thomas Barry","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075344817","display_name":"Doris Peterkin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Doris Peterkin","raw_affiliation_strings":["OncoPep, North Andover, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OncoPep, North Andover, MA;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"TPS1126","last_page":"TPS1126"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.6640999913215637,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.6640999913215637,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.30320000648498535,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.020999999716877937,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.984000027179718},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9589999914169312},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.7519999742507935},{"id":"https://openalex.org/keywords/hla-a2","display_name":"HLA-A2","score":0.7919999957084656},{"id":"https://openalex.org/keywords/xbp1","display_name":"XBP1","score":0.6830000281333923},{"id":"https://openalex.org/keywords/syndecan-1","display_name":"syndecan-1","score":0.9269999861717224},{"id":"https://openalex.org/keywords/cs1","display_name":"CS1","score":0.9139999747276306},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.7570000290870667},{"id":"https://openalex.org/keywords/vaccine-safety","display_name":"vaccine safety","score":0.5329999923706055},{"id":"https://openalex.org/keywords/immune-response","display_name":"immune response","score":0.8769999742507935},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.5630000233650208},{"id":"https://openalex.org/keywords/residual-disease","display_name":"residual disease","score":0.5329999923706055}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8750700950622559},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.6242315769195557},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.5697228908538818},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.49022966623306274},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4833030700683594},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.4788948595523834},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4320601224899292},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.41523319482803345},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4032916724681854},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3242546319961548},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.31482475996017456},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.20102843642234802}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.tps1126","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps1126","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps1126","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3010645285","https://openalex.org/W4220815396","https://openalex.org/W2947299562","https://openalex.org/W4410818569","https://openalex.org/W2939685075","https://openalex.org/W3127886518","https://openalex.org/W3116158596","https://openalex.org/W3008580471","https://openalex.org/W4322769719","https://openalex.org/W4220927199"],"abstract_inverted_index":{"TPS1126":[0],"Background:":[1],"Stage":[2],"2-3":[3,130],"triple":[4],"negative":[5],"breast":[6],"cancer":[7],"(TNBC)":[8],"remains":[9],"at":[10,149,159,252],"high":[11],"risk":[12],"for":[13,22,128],"recurrence":[14],"despite":[15],"modern":[16],"adjuvant":[17,126,175],"therapy.":[18,265],"An":[19],"important":[20],"role":[21],"the":[23,61,160,197,202,205,212,223,237,290],"immune":[24,62,89,213],"system":[25],"in":[26,50,64,91,96,105,141,222,268,316],"TNBC":[27],"has":[28,226],"recently":[29],"emerged.":[30],"Tumor":[31],"infiltrating":[32],"lymphocytes":[33],"(TILs)":[34],"are":[35,54,102,331,336],"correlated":[36],"with":[37,146,289],"improved":[38],"prognosis":[39],"and":[40,82,87,100,144,152,162,182,199,204,259,311,325,329],"several":[41],"PD-1/PD-L1":[42],"checkpoint":[43],"inhibitors,":[44],"including":[45,67,322],"Durvalumab":[46],"(DUR),":[47],"demonstrated":[48],"activity":[49],"metastatic":[51],"TNBC.":[52,68,106,131],"Vaccines":[53],"a":[55,72,92,227,276,300],"promising":[56],"approach":[57],"to":[58,195,210,215,244,274,284],"further":[59],"enhance":[60],"response":[63,214,248,295,310],"many":[65],"cancers":[66],"PVX-410":[69],"(PVX)":[70],"is":[71,194,209],"novel":[73],"tetra-peptide":[74],"vaccine":[75,164],"against":[76],"XBP1":[77,99],"(2":[78],"splice":[79],"variants),":[80],"CD138":[81,101],"CS1":[83],"that":[84],"was":[85,189],"safe":[86],"induced":[88],"responses":[90],"phase":[93],"1b":[94,110],"study":[95,114],"smoldering":[97],"myeloma.":[98],"also":[103],"over-expressed":[104],"Methods:":[107],"This":[108],"Phase":[109],"multi-center,":[111],"single":[112],"arm":[113],"will":[115,133,242,249,296],"enroll":[116],"20":[117,245,269],"HLA-A2+":[118],"female":[119],"patients":[120],"(pts)":[121],"following":[122],"completion":[123],"of":[124,137,155,201,278,304],"all":[125],"therapy":[127,188],"stage":[129],"Pts":[132],"receive":[134],"6":[135,225],"doses":[136,154],"800ug":[138],"PVX":[139,216],"(emulsified":[140],"Montanide":[142],"(SC)":[143],"co-administered":[145],"Hiltonol":[147],"(IM))":[148],"2-week":[150],"intervals,":[151],"2":[153],"DUR":[156,239],"1500mg":[157],"IV":[158],"4th":[161],"6th":[163],"visits.":[165],"Eligible":[166],"pts":[167,270,335],"must":[168],"be":[169,250,297],"between":[170],"1-6":[171],"months":[172],"from":[173,282],"completing":[174,263],"therapy,":[176],"have":[177,183],"no":[178],"prior":[179],"autoimmune":[180],"disease,":[181],"residual":[184],"disease":[185],"if":[186],"neoadjuvant":[187],"used.":[190],"The":[191],"primary":[192],"objective":[193,208],"determine":[196,211],"safety":[198],"tolerability":[200],"combination,":[203],"key":[206],"secondary":[207],"+":[217],"DUR.":[218],"If":[219],"\u22641":[220],"pt":[221],"first":[224,238],"protocol":[228,264],"defined":[229],"dose":[230],"limiting":[231],"toxicity":[232],"within":[233],"4":[234,255,260,285,334],"weeks":[235,261,286],"after":[236,262],"dose,":[240],"accrual":[241],"continue":[243],"pts.":[246],"Immune":[247,294],"assessed":[251],"baseline,":[253],"pre-dose":[254],"PVX/dose":[256],"1":[257],"DUR,":[258],"Paired":[266],"data":[267],"provides":[271],"90%":[272],"power":[273],"see":[275],"shift":[277],"0.75":[279],"standardized":[280],"units":[281],"baseline":[283],"post":[287],"treatment":[288],"signed":[291],"rank":[292],"test.":[293],"determined":[298],"by":[299],"FACs":[301],"based":[302],"assay":[303],"antigen":[305],"specific":[306],"CD3+CD8+":[307],"T":[308],"lymphocyte":[309],"IFN-\u03b3":[312],"production":[313],"(intracellular":[314],"staining)":[315],"patient":[317],"PBMCs.":[318],"Additional":[319],"correlative":[320],"studies,":[321],"T-cell":[323],"PD-1":[324],"tissue":[326],"PD-L1,":[327],"XBP1,":[328],"CD138,":[330],"planned.":[332],"Currently":[333],"enrolled.":[337],"Clinical":[338],"trial":[339],"information:":[340],"NCT02826434.":[341]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-06-15T00:00:00"}